Vaccine Makers Set to Tell Congress Supply Strains Ebbing

Ref: Financial Post
  • In testimony submitted for a US Congressional hearing scheduled for Tuesday, vaccine makers indicated that some of the major bottlenecks that have hampered the country's immunization campaign could soon begin to ease, as reported in the Financial Post.

  • Moderna said the FDA could allow it to put as many as 15 doses of its COVID-19 vaccine into each vial, which currently holds 10 doses. If authorized, the change could quickly boost supply of┬ámRNA-273, as one of the main production bottlenecks for Moderna has been at vial-filling plants.

  • Meanwhile, Pfizer said improvements and expansions to its vaccine manufacturing effort could allow it to ship 13 million doses of BNT162b2 a week by mid-March, up from 4 million to 5 million doses a week in early February.

  • Chief business officer John Young also indicated that by the end of July, it should be able to ship all 300 million doses it is contracted to provide in the US, enough to vaccinate 150 million people.

  • In its statement, Johnson & Johnson said it may be able to make enough of its one-dose candidate vaccine Ad26.COV2.S, currently under review by the FDA, to inoculate more than 20 million Americans by the end of March.

  • At the hearing on Tuesday, vaccine makers are also expected to discuss other ways to boost COVID-19 vaccine supply, such as by reaching agreements with contract manufacturers and creating partnerships across the industry to secure additional capacity.